ブフェキサマク、ブフェキサマック
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/12/28 01:45:27」(JST)
[Wiki en表示]
Bufexamac
|
| Systematic (IUPAC) name |
|
2-(4-butoxyphenyl)-N-hydroxyacetamide
|
| Clinical data |
| AHFS/Drugs.com |
International Drug Names |
| Legal status |
|
Routes of
administration |
Topical, rectal |
| Pharmacokinetic data |
| Excretion |
Renal |
| Identifiers |
| CAS Number |
2438-72-4 |
| ATC code |
M01AB17 M02AA09 |
| PubChem |
CID: 2466 |
| IUPHAR/BPS |
7498 |
| ChemSpider |
2372 |
| UNII |
4T3C38J78L Y |
| KEGG |
D01271 |
| ChEMBL |
CHEMBL94394 |
| Chemical data |
| Formula |
C12H17NO3 |
| Molecular mass |
223.268 g/mol |
|
|
InChI
-
InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
-
Key:MXJWRABVEGLYDG-UHFFFAOYSA-N
|
Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Common brand names include Paraderm and Parfenac. It was withdrawn in Europe because of allergic reactions.
Contents
- 1 Indications
- 2 Pharmacology
- 3 Side effects
- 4 References
Indications
Ointments and lotions containing bufexamac are used for the treatment of subacute and chronic eczema of the skin, including atopic eczema, as well as sunburn and other minor burns,[citation needed] and itching. Suppositories containing bufexamac in combination with local anaesthetics are used against haemorrhoids.[1]
Pharmacology
Bufexamac is thought to act by inhibiting the enzyme cyclooxygenase, which would make it a non-steroidal anti-inflammatory drug. Evidence on the mechanism of action is scarce.[2] Furthermore, bufexamac was identified as a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10).[3]
Side effects
Bufexamac can cause severe contact dermatitis which is often hard to distinguish from the initial condition.[4] As a consequence, the European Medicines Agency recommended to withdraw the marketing approval in April 2010.[5]
References
- ^ Dinnendahl, V, Fricke, U, ed. (2010). Arzneistoff-Profile (in German) 2 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
- ^ Gloor, Max; Thoma, Karl; Fluhr, Joachim (2000). Dermatologische Externatherapie: Unter besonderer Berücksichtigung der Magistralrezeptur (in German). Springer. p. 349. ISBN 3-540-67174-9.
- ^ Bantscheff, Marcus; Hopf, Carsten; Savitski, Mikhail M; Dittmann, Antje; Grandi, Paola; Michon, Anne-Marie; Schlegl, Judith; Abraham, Yann; Becher, Isabelle; Bergamini, Giovanna; Boesche, Markus; Delling, Manja; Dümpelfeld, Birgit; Eberhard, Dirk; Huthmacher, Carola; Mathieson, Toby; Poeckel, Daniel; Reader, Valérie; Strunk, Katja; Sweetman, Gavain; Kruse, Ulrich; Neubauer, Gitte; Ramsden, Nigel G; Drewes, Gerard (2011). "Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes". Nature Biotechnology 29 (3): 255–65. doi:10.1038/nbt.1759. PMID 21258344.
- ^ "Bufexamac: Ein Ekzemtherapeutikum, das selbst häufig allergische Kontaktekzeme hervorruft". Deutsches Ärzteblatt (in German) (47). 2000.
- ^ "European Medicines Agency recommends revocation of marketing authorisations for bufexamac" (PDF). European Medicines Agency. 2010-04-22.
|
Topical products for joint and muscular pain (M02)
|
|
Anti-inflammatory
preparations,
non-steroids |
| Pyrazolidines |
- Phenylbutazone
- Mofebutazone
- Clofezone
- Oxyphenbutazone
|
|
Acetic acid
derivatives |
- Tolmetin
- Diclofenac
- Fentiazac
|
|
| Other |
- Benzydamine
- Etofenamate
- Piroxicam
- Felbinac
- Bufexamac
- Ketoprofen
- Bendazac
- Naproxen
- Ibuprofen
- Feprazone
- Niflumic acid
- Meclofenamic acid
- Flurbiprofen
- Suxibuzone
- Indometacin
- Nifenazone
|
|
|
| Capsaicin derivatives |
|
|
| Other |
- Tolazoline
- Dimethyl sulfoxide
- Idrocilamide
|
|
|
Index of joint
|
|
| Description |
- Anatomy
- head and neck
- cranial
- arms
- torso and pelvis
- legs
- bursae and sheathes
- Physiology
|
|
| Disease |
- Arthritis
- acquired
- back
- childhood
- soft tissue
- Congenital
- Injury
- Symptoms and signs
- Examination
|
|
| Treatment |
- Procedures
- Drugs
- rheumatoid arthritis
- gout
- topical analgesics
|
|
|
|
Prostanoid signaling
|
|
Receptor
(ligands) |
|
|
Enzyme
(inhibitors) |
| Cyclooxygenase |
|
|
| PGD2 synthase |
- Retinoids
- Selenium (selenium tetrachloride, sodium selenite, selenium disulfide)
|
|
| PGE synthase |
HQL-79
|
|
| PGF synthase |
Bimatoprost
|
|
| PGI2 synthase |
Tranylcypromine
|
|
| TXA synthase |
- Camonagrel
- Dazmegrel
- Dazoxiben
- Furegrelate
- Isbogrel
- Midazogrel
- Nafagrel
- Nicogrelate
- Ozagrel
- Picotamide
- Pirmagrel
- Ridogrel
- Rolafagrel
- Samixogrel
- Terbogrel
- U63557A
|
|
|
| Others |
- Precursors: Linoleic acid
- γ-Linolenic acid (gamolenic acid)
- Dihomo-γ-linolenic acid
- Diacylglycerol
- Arachidonic acid
- Prostaglandin G2
- Prostaglandin H2
|
|
|
See also: Leukotrienergics
|
|
English Journal
- The first Australian Baseline Series: Recommendations for patch testing in suspected contact dermatitis.
- Toholka R1, Wang YS, Tate B, Tam M, Cahill J, Palmer A, Nixon R.
- The Australasian journal of dermatology.Australas J Dermatol.2015 May;56(2):107-15. doi: 10.1111/ajd.12186. Epub 2014 Sep 7.
- BACKGROUND AND OBJECTIVES: Patch testing is a standard diagnostic tool used in the identification of causative allergens in allergic contact dermatitis. Ongoing surveillance of rates of allergen positivity is vitally important to detect trends and allow comparisons between countries. The objective o
- PMID 25196101
- Acetylation site specificities of lysine deacetylase inhibitors in human cells.
- Schölz C1, Weinert BT1, Wagner SA1, Beli P1, Miyake Y2, Qi J3, Jensen LJ4, Streicher W5, McCarthy AR6, Westwood NJ7, Lain S6, Cox J8, Matthias P2, Mann M8, Bradner JE3, Choudhary C1.
- Nature biotechnology.Nat Biotechnol.2015 Apr;33(4):415-23. doi: 10.1038/nbt.3130. Epub 2015 Mar 9.
- Lysine deacetylases inhibitors (KDACIs) are used in basic research, and many are being investigated in clinical trials for treatment of cancer and other diseases. However, their specificities in cells are incompletely characterized. Here we used quantitative mass spectrometry (MS) to obtain acetylat
- PMID 25751058
- Current trends in patch testing - new data from the German Contact Dermatitis Research Group (DKG) and the Information Network of Departments of Dermatology (IVDK).
- Mahler V1, Geier J, Schnuch A.
- Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.J Dtsch Dermatol Ges.2014 Jul;12(7):583-92. doi: 10.1111/ddg.12371.
- BACKGROUND AND OBJECTIVES: The relevance of contact allergens is subject to constant change due to changing exposures according to consumers' preferences and legal requirements. The objective of this paper is to present trends in contact sensitization from the DKG and IVDK patch test clinics, which
- PMID 24981472
Japanese Journal
- 症例 ブフェキサマク含有クリームを顔面塗布後に喉頭浮腫を合併した接触皮膚炎症候群の1例
- 昭和大学皮膚科において1990~2010年に施行された外用薬のパッチテスト結果の解析
- 長村 蔵人,北見 由季,末木 博彦 [他]
- 昭和学士会雑誌 = Journal of the Showa University Society 73(4), 375-381, 2013-08
- NAID 40020029823
- 昭和大学皮膚科において1990～2010年に施行された外用薬のパッチテスト結果の解析
- 長村 蔵人,北見 由季,末木 博彦,中田 土起丈,保坂 浩臣
- 昭和学士会雑誌 73(4), 375-381, 2013
- 1990年4月より2010年3月までの20年間に昭和大学病院附属東病院皮膚科を受診し，外用薬による接触皮膚炎が疑われパッチテストを施行された316名（男101名，女215名，平均年齢50.1歳，SD 21.8歳）を対象とした．対象者の疾患は湿疹・皮膚炎群が277名（87.7%）で，そのうち242名（76.6%）は接触皮膚炎であった．パッチテストは被疑薬剤を軟膏，クリーム基剤はFin Chamber …
- NAID 130004627322
Related Links
- Name Language First published Last updated Questions and answers on the revocation of the marketing authorisations for medicines containing Bufexamac - Outcome of a procedure under Article 107 of Directive 2001/83/EC BG ...
- Buy Bufexamac (CAS 2438-72-4), a specialty product for proteomics research, from Santa Cruz. Molecular Formula: C12H17NO3, Molecular Weight: 223.27 ... Bufexamac is a specific inhibitor of HDAC6 and HDAC10. Treatment of ...
Related Pictures
★リンクテーブル★
[★]
- 英
- bufexamac
- 商
- アンダーム、サリベドール、デムコ、ルブラゾン
- 関
- ブフェキサマック
[★]
- 英
- bufexamac
- 関
- ブフェキサマク